151 related articles for article (PubMed ID: 11806282)
21. Plasminogen activator inhibitor type-1 controls the process of the in vitro sprout formation.
Chorostowska-Wynimko J; Skrzypczak-Jankun E; Jankun J
J Physiol Pharmacol; 2004 Sep; 55 Suppl 3():49-56. PubMed ID: 15611593
[TBL] [Abstract][Full Text] [Related]
22. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism.
Roca C; Primo L; Valdembri D; Cividalli A; Declerck P; Carmeliet P; Gabriele P; Bussolino F
Cancer Res; 2003 Apr; 63(7):1500-7. PubMed ID: 12670896
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review).
Chorostowska-Wynimko J; Skrzypczak-Jankun E; Jankun J
Int J Mol Med; 2004 Jun; 13(6):759-66. PubMed ID: 15138609
[TBL] [Abstract][Full Text] [Related]
24. Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1).
Lademann UA; Rømer MU
Thromb Haemost; 2008 Dec; 100(6):1041-6. PubMed ID: 19132228
[TBL] [Abstract][Full Text] [Related]
25. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
Bajou K; Masson V; Gerard RD; Schmitt PM; Albert V; Praus M; Lund LR; Frandsen TL; Brunner N; Dano K; Fusenig NE; Weidle U; Carmeliet G; Loskutoff D; Collen D; Carmeliet P; Foidart JM; Noël A
J Cell Biol; 2001 Feb; 152(4):777-84. PubMed ID: 11266468
[TBL] [Abstract][Full Text] [Related]
26. The plasminogen activator inhibitor "paradox" in cancer.
Binder BR; Mihaly J
Immunol Lett; 2008 Jun; 118(2):116-24. PubMed ID: 18495253
[TBL] [Abstract][Full Text] [Related]
27. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
28. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.
Maillard C; Jost M; Rømer MU; Brunner N; Houard X; Lejeune A; Munaut C; Bajou K; Melen L; Dano K; Carmeliet P; Fusenig NE; Foidart JM; Noel A
Neoplasia; 2005 Jan; 7(1):57-66. PubMed ID: 15720817
[TBL] [Abstract][Full Text] [Related]
29. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
Inoue M; Sawada T; Uchima Y; Kimura K; Nishihara T; Tanaka H; Yashiro M; Yamada N; Ohira M; Hirakawa K
Oncol Rep; 2005 Dec; 14(6):1445-51. PubMed ID: 16273237
[TBL] [Abstract][Full Text] [Related]
31. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
32. Protein C and its inhibitor in malignancy.
Suzuki K; Hayashi T
Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
[TBL] [Abstract][Full Text] [Related]
33. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.
Wind T; Hansen M; Jensen JK; Andreasen PA
Biol Chem; 2002 Jan; 383(1):21-36. PubMed ID: 11928815
[TBL] [Abstract][Full Text] [Related]
34. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease.
Agirbasli M
Int J Clin Pract; 2005 Jan; 59(1):102-6. PubMed ID: 15707473
[TBL] [Abstract][Full Text] [Related]
35. Plasmin/plasminogen system in colorectal cancer.
Berger DH
World J Surg; 2002 Jul; 26(7):767-71. PubMed ID: 11965442
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator inhibitor-1 deficiency enhances flow-induced smooth muscle cell migration.
Cullen JP; Nicholl SM; Sayeed S; Sitzmann JV; Okada SS; Cahill PA; Redmond EM
Thromb Res; 2004; 114(1):57-65. PubMed ID: 15262486
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen activator inhibitor-1 modulates adipocyte differentiation.
Liang X; Kanjanabuch T; Mao SL; Hao CM; Tang YW; Declerck PJ; Hasty AH; Wasserman DH; Fogo AB; Ma LJ
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E103-E113. PubMed ID: 16144810
[TBL] [Abstract][Full Text] [Related]
38. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
40. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA
J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
